Dihydroartemisinin alleviates atopic dermatitis in mice by inhibiting mast cell infiltration.
10.12122/j.issn.1673-4254.2020.10.14
- Author:
Xue XUE
1
;
Zheyu DONG
1
;
Yu DENG
1
;
Shuxian YIN
2
;
Ping WANG
1
;
Yanxia LIAO
2
;
Guodong HU
2
;
Yinghua CHEN
1
Author Information
1. Department of Histology and Embryology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.
2. Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
- Publication Type:Journal Article
- Keywords:
2, 4-Dinitrochlorobenzene;
atopic dermatitis;
dihydroartemisinin;
mast cells
- MeSH:
Animals;
Anti-Inflammatory Agents/therapeutic use*;
Artemisinins;
Cytokines;
Dermatitis, Atopic/drug therapy*;
Immunoglobulin E;
Mast Cells;
Mice;
Mice, Inbred BALB C;
Mice, Inbred C57BL;
Skin
- From:
Journal of Southern Medical University
2020;40(10):1480-1487
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the therapeutic effect of different doses of dihydroartemisinin (DHA) on atopic dermatitis (AD) in mice and explore the mechanism.
METHODS:Forty-two C57BL/6 mice were randomly divided into 7 groups (
RESULTS:Treatment with 25, 75, and 125 mg/kg DHA and dexamethasone all alleviated AD symptoms of mice, reduced the severity scores of skin lesions, and ameliorated pathological changes of the skin tissue. DHA at 125 mg/kg produced the most obvious therapeutic effect and significantly alleviated mast cell infiltration in the lesions as compared with the other treatment groups (
CONCLUSIONS:DHA is effective for the treatment of AD in mice with an optimal dose of 125 mg/kg. The therapeutic effect of DHA is achieved probably through regulation of local immunity by inhibiting mast cell infiltration in the lesions.
